<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289652</url>
  </required_header>
  <id_info>
    <org_study_id>PROBE-C V 2.3, 03 June 20</org_study_id>
    <secondary_id>NEAT</secondary_id>
    <nct_id>NCT01289652</nct_id>
  </id_info>
  <brief_title>The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals</brief_title>
  <acronym>PROBE-C</acronym>
  <official_title>PRospective OBservational Evaluation of the Natural History and Treatment of Acute HCV in HIV-positive Individuals: The PROBE-C Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benedetta Mattioli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the epidemiology, natural history and treatment&#xD;
      outcomes of acute hepatitis C (HCV) infection. Given the current pattern of case reporting,&#xD;
      the cohort will be largely made up of human immunodeficiency virus (HIV)-positive patients,&#xD;
      but HIV-negative patients with acute hepatitis C (AHC) will also be enrolled to enable&#xD;
      comparisons to be made as appropriate and possible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a multi-center, prospective, open cohort study, patients with documented acute hepatitis C&#xD;
      infection will be followed prospectively over an initial time-period of 3 years after&#xD;
      diagnosis of acute hepatitis C infection to investigate:&#xD;
&#xD;
        1. epidemiology&#xD;
&#xD;
             -  to describe the characteristics of patients who have acquired acute HCV infection,&#xD;
                including examination of regional differences in modes of transmission, behavioural&#xD;
                factors, concomitant sexually transmitted diseases, clinical presentation and&#xD;
                associated laboratory test results.&#xD;
&#xD;
             -  characterization of the HCV strains circulating within the community using&#xD;
                phylogenetic analysis&#xD;
&#xD;
        2. natural history&#xD;
&#xD;
             -  determination of the rate of spontaneous viral clearance, and the clinical,&#xD;
                immunological, host genetic and viral factors associated with viral clearance&#xD;
&#xD;
             -  progression of liver disease after acute hepatitis C; including the use of&#xD;
                non-invasive liver fibrosis markers to estimate rates of liver fibrosis progression&#xD;
&#xD;
        3. treatment strategies&#xD;
&#xD;
             -  describe the outcome of different treatment strategies for acute HCV infection,&#xD;
                although it is acknowledged that there will be no random allocation of treatment&#xD;
                strategies.&#xD;
&#xD;
             -  investigate factors associated with treatment response including time to initiation&#xD;
                of therapy, duration of therapy, the use of ribavirin and genetic factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SVR</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HCV + HIV</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For phylogenetic analysis HCV RNA detection will be performed.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        600 acute HCV infections with/without HIV infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented current or past acute hepatitis C infection with detectable HCV-RNA&#xD;
             (PCR-assay) with an estimated duration of 52 weeks at diagnosis as defined below:&#xD;
&#xD;
               -  First HCV RNA positive AND&#xD;
&#xD;
               -  Prior negative anti-HCV antibody or HCV RNA test within 12 months OR&#xD;
&#xD;
               -  Rise of liver transaminases above 2.5 x upper limit of normal (ULN) within the&#xD;
                  past 12 months with prior normal transaminases during the year before AND&#xD;
&#xD;
               -  Exclusion of other causes of acute hepatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute liver disease other than hepatitis C&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Younger than 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juergen K Rockstroh, MD</last_name>
    <email>juergen.rockstroh@ukb.uni-bonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Boesecke, MD</last_name>
    <email>christoph.boesecke@ukb.uni-bonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bonn University Hospital</name>
      <address>
        <city>Bonn</city>
        <state>NSW</state>
        <zip>53129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Boesecke, MD</last_name>
      <email>christoph.boesecke@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Juergen K Rockstroh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Benedetta Mattioli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute hepatitis C (HCV)</keyword>
  <keyword>Human immunodeficiency virus (HIV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

